Mesoblast Limited (MESO) vs Septerna, Inc. (SEPN)
- Mesoblast Limited MESO 13.28 −4.80%
- Septerna, Inc. SEPN 36.05 −3.74%
Mesoblast Limited and Septerna, Inc. are both Biotechnology companies. Mesoblast Limited and Septerna, Inc. are of similar size ($1.8B and $1.8B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against −26.5%. Septerna, Inc. has the higher net margin (−24.5% vs −1,091.7%) and the lower return on invested capital (−189.0% vs 0.00%). Across the 17 metrics below, Septerna, Inc. leads on 12 and Mesoblast Limited on 5.
Valuation
Profitability
| Metric | MESO | SEPN | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 100.00% | 65.16% |
| Operating margin | (826.28%) | (44.04%) | 0.00% |
| Net margin | (1,091.71%) | (24.51%) | 0.00% |
| Free cash flow margin | 0.00% | 118.93% | 0.00% |
| Return on equity | 0.00% | (6.34%) | (56.36%) |
| Return on assets | 0.00% | (4.94%) | (48.04%) |
| Return on invested capital | 0.00% | (189.01%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack